Experienced in Neuronal Intranuclear Inclusion Disease (NIID)

Yoshihiro Maegaki

Yonago, JP 
Experienced in Neuronal Intranuclear Inclusion Disease (NIID)
Yonago, JP 
OverviewLocationsClinical Research

Overview

Yoshihiro Maegaki practices in Yonago, Japan. Mr. Maegaki is rated as an Experienced expert by MediFind in the treatment of Neuronal Intranuclear Inclusion Disease (NIID). His top areas of expertise are Genetic Epilepsy with Febrile Seizures Plus (GEFS+), West Syndrome, Seizures, Spasmus Nutans, and Gastrostomy.

His clinical research consists of co-authoring 139 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Neuronal Intranuclear Inclusion Disease (NIID).

Gender
Male

Locations

Yonago, Japan
Other Locations
Tottori, Japan
Tokyo, Japan
Nagoya, Japan
Fukuoka, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
Enrollment Status: Completed
Publish Date: January 18, 2024
Intervention Type: Drug
Study Drug: Ataluren
Study Phase: Phase 3
A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in Community Settings
A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in Community Settings
Enrollment Status: Completed
Publish Date: September 14, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in the Hospital or Emergency Room
A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in the Hospital or Emergency Room
Enrollment Status: Completed
Publish Date: July 31, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

139 Total Publications

A patient presenting with chapeau de gendarme and three phase-ictal EEG pattern: Suggesting a focus in the interhemispheric fissure.
A patient presenting with chapeau de gendarme and three phase-ictal EEG pattern: Suggesting a focus in the interhemispheric fissure.
Journal: Brain & development
Published: August 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Maegaki's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 82 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile